Verastem Oncology Inc. CEO Dan Paterson said he is “not expecting a huge bolus [of ovarian cancer patients] at the beginning” of Avmapki/Fakzynja’s launch, but momentum will build over time. “Based on our market research, this [drug] is the most likely thing for them to go on next,” he added, noting that patients tend to be on the drug for an average of 18 months.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Bioarctic, JCR, Medipal, Valneva, Viridian.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, ALX, BMS, Cassava, Evotec, Gilead, Korro, Mira, Novavax, Peptone, Phosphorex, Rallybio, Ratio, Scenic, Vor.
New hires and promotions in the biopharma industry, including: Context, Eli Lilly, Novavax, Pathos AI, Phoremost, Revolution, Seamless, Sibylla, Synnovation.
In April, biopharma transactions amounted to $12.8 billion, a sharp decline from March’s $29.48 billion. However, with $79.66 billion in deal value during the first four months of 2025, the sector has already achieved its highest start to a year in BioWorld’s records since 2019.
Finding that a lower court went too far with an injunction that ignores the Hatch-Waxman safe harbor protections for drug development, the U.S. Court of Appeals for the Federal Circuit handed Avadel CNS Pharmaceuticals LLC a win of sorts.
RSS
